Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …

The outcome of conventional therapy in MM is highly heterogeneous and appears to be
largely dictated by the presence of recurrent genomic aberrations. Among these t (4; 14) …

We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma
(NDMM/RRMM) patients with del (17p). Thirteen prospective studies that evaluated 3,187 …

We read with interest the publication by Liu et al. reporting the results from a meta‑analysis
of 13 prospective studies evaluating the efficacy of proteasome inhibitor/immunomodulatory …

Introduction High risk (HR) multiple myeloma (MM) constitutes approximately 25% of newly
diagnosed patients and is a subgroup of MM patients that is variably defined. Patients with …

The chromosomal abnormalities of del (13), t (4; 14), and del (17p) are associated with poor
progression-free survival (PFS) and shorter overall survival (OS) in newly diagnosed …

Introduction Improvement in overall survival (OS) is seen primarily within standard risk
Multiple Myeloma (MM), however, high risk MM OS was still around 2-3 years until recently …

Abstract Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) which
specifically targets XPO1 (Exportin 1)-mediated nuclear export, leading to increased nuclear …

Background: Exportin 1 (XPO1) is involved in the nuclear export of tumor suppressor
proteins (TSPs) and associated with poor prognosis and drug resistance in multiple …

Introduction-The nuclear export protein exportin 1 (XPO1) is overexpressed in a wide variety
of cancers including multiple myeloma (MM). Selinexor is a first-in-class Selective Inhibitor of …